title: Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonist.
abstract: Episomal plasmids (p8901) with minigenes coding for the influenza virus matrix peptide amino acids 57-68 (KGILGFVFTLTV; referred to as M57-68) or coding for a modified peptide were introduced into HLA-A2-positive target cells. The association of these peptides, synthesized in the cytoplasm, with HLA-A2 and the expression of this complex at the cell surface was evaluated with HLA-A2-restricted CTL specific for the influenza virus matrix peptide M57-68. Cells expressing M57-68 were lysed effectively, as were cells expressing a peptide that retained residues 60-64 with seven flanking alanine residues (AAALGFVFAAAA). An exogenously added synthetic analog of peptide M57-68 that inhibited sensitization of targets with synthetic peptide M57-68 also inhibited lysis of cells expressing the minigene coding for the peptide with seven alanine substitutions. These results demonstrate the utility of minigene DNA constructs in creating experimental systems to develop agents to diminish the severity of CTL-mediated tissue damage in autoimmune diseases and graft rejection.
authors.affiliation: Merck Sharp and Dohme Research Laboratories, Rahway, NJ 07065.
authors.forename: M C
authors.initials: MC
authors.lastname: Gammon
authors.forename: M A
authors.initials: MA
authors.lastname: Bednarek
authors.forename: W E
authors.initials: WE
authors.lastname: Biddison
authors.forename: S S
authors.initials: SS
authors.lastname: Bondy
authors.forename: J D
authors.initials: JD
authors.lastname: Hermes
authors.forename: G E
authors.initials: GE
authors.lastname: Mark
authors.forename: A R
authors.initials: AR
authors.lastname: Williamson
authors.forename: H J
authors.initials: HJ
authors.lastname: Zweerink
mesh_terms: D000595:Amino Acid Sequence; D000938:Antigen-Presenting Cells / Q000276:immunology; D000956:Antigens, Viral / Q000737:chemistry / Q000378:metabolism*; D001483:Base Sequence; D001667:Binding, Competitive; D003001:Cloning, Molecular; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D005822:Genetic Vectors; D015789:HLA-A2 Antigen / Q000378:metabolism*; D006801:Humans; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D009980:Influenza A virus / Q000276:immunology*; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000737:chemistry; D010455:Peptides / Q000276:immunology* / Q000378:metabolism; D010957:Plasmids; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014763:Viral Matrix Proteins / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism
chemical_list: D000956:Antigens, Viral; D015789:HLA-A2 Antigen; D009838:Oligodeoxyribonucleotides; D010455:Peptides; D014763:Viral Matrix Proteins